



PRESS RELEASE

Investment of Advanced Accelerator Applications in Atreus Pharmaceuticals Corporation to develop Annexin Imaging Business

Saint Genis Pouilly, France (March 2, 2010) -- Advanced Accelerator Applications ("AAA") -www.adacap.com-, a European leader in diagnostic nuclear medicine, announced its investment in Atreus Pharmaceuticals Corporation - www.atreuspharma.com- of up to approximately US\$ 6 million. AAA's investment will be made in stages depending on the accomplishment of certain research and regulatory milestones. Proceeds of the injection of capital will be used to expand Atreus' research in launching its proprietary line of products aimed at molecular imaging based on Annexin V.

Atreus, formed in 2008, is a development-stage, biopharmaceutical company headquartered in Ottawa, Canada. Atreus develops in-vivo radiopharmaceutical products suitable for Nuclear Medicine (SPECT) imaging and for PET imaging that will aid in the early diagnosis and management of diseases including rheumatoid arthritis ("RA"). Early diagnosis can be crucial to effective treatment with disease modifying drugs which may prevent loss of function and result in improved quality of life for the patient. Atreus' mission is to develop proprietary molecular imaging products based on Annexin V, an endogenous human protein which binds to phosphatidylserine, a molecule expressed only on the surface of dead or dying cells (apoptotic and necrotic cells). Annexin, labeled with Technetium-99m (Tc-99m), a medical isotope widely used in diagnostic imaging, has been studied extensively in both animals and humans. Tc-99m labelled Annexin has demonstrated the ability to image cellular apoptosis and necrosis – conditions associated with a variety of debilitating or fatal medical conditions including rheumatoid arthritis, Crohn's disease, Alzheimer's disease, myocarditis, cardiac transplant rejection, acute myocardial infarction and unstable atherosclerotic carotid artery disease. In addition, Tc-99m labelled Annexin has been used to evaluate the response to treatment for lymphoma and lung cancer. Atreus' technology is being exploited as part of its proprietary license issued by Stanford University, Palo Alto, California.

France-based Advanced Accelerator Applications, created in 2002, is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA has extensive experience in developing innovative diagnostic and therapeutic applications and products. The company's primary focus is on products addressing Molecular Imaging and Therapy for the personalized treatment of serious diseases (widely known as "Personalized Medicine").

AAA currently has eight production and R&D facilities in 4 countries (France, Italy, Switzerland and Spain), more than 120 employees and approximately € 25 million in annual turnover.



AAA was the 2009 recipient of the Deloitte First Place Prize for the highest company growth of the “Deloitte Technology Fast 50” in its home Region of Rhône-Alpes/Auvergne.

Stefano Buono, President and Chief Executive Officer of AAA, stated that the investment in Atreus “is a natural fit for our company and its goals of expanding both in product extension and geographically into the highly promising North American market. AAA’s strategy is to grow via internal product development and selected external investments in companies that demonstrate a compatibility with our high-margin, high-growth businesses. We expect that Atreus’ unique and sophisticated research combined with its excellent management team will contribute significantly to AAA’s future plans”.

Mr. Buono’s confidence in the transaction was reinforced by remarks from Atreus’ Chief Executive Officer Bill Dickie “This agreement provides for financial support by a premier European partner for the continued development of Atreus’ technology through phase 2 clinical studies, which are expected to demonstrate proof of principle of the pharmaceutical for RA. Both companies will benefit from the fact that AAA will acquire and invest in an exclusive option for EU marketing and distribution of the proprietary technology and will be responsible for conducting pivotal studies and for regulatory approval in the EU.”

Mr. Buono further indicated that this investment could be only the beginning of an increasingly aggressive growth strategy not only for its diagnostics sector but into therapeutics as well.

Nuclear Medicine

Nuclear medicine is a growing medical specialty that relies on using very small amounts of molecular probes, called radiotracers, to create images of the body and its organs or to treat them. The technique works by tracking radioactive chemicals that are injected into the patient’s body, where they accumulate in the organ or tissue of interest and reveal biochemical changes.

Nuclear medicine employs a variety of imaging devices and therapeutics that use radionuclides. PET and SPECT technologies enable physicians to diagnose different types of cancer, cardiovascular diseases, and neurological disorders in their early stages. These techniques are also a cheaper alternative to more invasive procedures such as biopsy or surgery. Nuclear imaging devices are also valuable for conducting research on the biology of human diseases and for developing and testing new treatment approaches.

Although nuclear medicine has already made significant contributions to biomedical research and disease monitoring, scientists are working to find ways to determine how well therapy is working in patients, enabling them to tailor treatments for individuals and their diseases, also known as “personalized medicine”. Nuclear Medicine has continuously improved to become an invaluable tool in the field of Personalized Molecular Medicine.



Contacts

Advanced Accelerator Applications
Véronique Mermet
20 rue Diesel
01630 Saint Genis Pouilly, France
Tel: +33 4 50 99 30 70
www.adacap.com
info@adacap.com

Atreus Pharmaceuticals Corporation
Bill Dickie
9 Hansen Avenue
Ottawa, Ontario, Canada K2K 2L9
Tel: +1 613 852-3217
www.atreuspharma.com
info@atreuspharma.com